Pharma company wages billion dollar war against generic drug for hepatitis V.

Brazil’s Ministry of Health announced earlier this year a new plan to eradicate hepatitis C from the country by 2030, and SUS (Brazil’s universal health care system) began treating all patients with the new antivirals, instead of giving it only to the most severe cases. But a full treatment with sofosbuvir, produced by US pharmaceutical company Gilead, costs up to R$ 35,000 (US$ 8,500) per patient, and this limits the number of people that can receive the medication. Gilead is blocking the purchase of a hepatitis C generic drug that would save the Brazilian government R$ 1 billion (US$ 275 million) a year.